162 related articles for article (PubMed ID: 16408696)
1. The antineoplastic efficacy of the prodrug Cloretazine is produced by the synergistic interaction of carbamoylating and alkylating products of its activation.
Baumann RP; Seow HA; Shyam K; Penketh PG; Sartorelli AC
Oncol Res; 2005; 15(6):313-25. PubMed ID: 16408696
[TBL] [Abstract][Full Text] [Related]
2. 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine (VNP40101M): II. Role of O6-alkylguanine-DNA alkyltransferase in cytotoxicity.
Baumann RP; Shyam K; Penketh PG; Remack JS; Brent TP; Sartorelli AC
Cancer Chemother Pharmacol; 2004 Apr; 53(4):288-95. PubMed ID: 14685775
[TBL] [Abstract][Full Text] [Related]
3. Role of O6-alkylguanine-DNA alkyltransferase in the cytotoxic activity of cloretazine.
Ishiguro K; Shyam K; Penketh PG; Sartorelli AC
Mol Cancer Ther; 2005 Nov; 4(11):1755-63. PubMed ID: 16275997
[TBL] [Abstract][Full Text] [Related]
4. 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine (VNP40101M): I. Direct inhibition of O6-alkylguanine-DNA alkyltransferase (AGT) by electrophilic species generated by decomposition.
Penketh PG; Shyam K; Baumann RP; Remack JS; Brent TP; Sartorelli AC
Cancer Chemother Pharmacol; 2004 Apr; 53(4):279-87. PubMed ID: 14704831
[TBL] [Abstract][Full Text] [Related]
5. Mode of action of the chloroethylating and carbamoylating moieties of the prodrug cloretazine.
Ishiguro K; Seow HA; Penketh PG; Shyam K; Sartorelli AC
Mol Cancer Ther; 2006 Apr; 5(4):969-76. PubMed ID: 16648568
[TBL] [Abstract][Full Text] [Related]
6. Differential inhibition of cellular glutathione reductase activity by isocyanates generated from the antitumor prodrugs Cloretazine and BCNU.
Rice KP; Penketh PG; Shyam K; Sartorelli AC
Biochem Pharmacol; 2005 May; 69(10):1463-72. PubMed ID: 15857610
[TBL] [Abstract][Full Text] [Related]
7. pH-dependent general base catalyzed activation rather than isocyanate liberation may explain the superior anticancer efficacy of laromustine compared to related 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazine prodrugs.
Penketh PG; Finch RA; Sauro R; Baumann RP; Ratner ES; Shyam K
Chem Biol Drug Des; 2018 Jan; 91(1):62-74. PubMed ID: 28636806
[TBL] [Abstract][Full Text] [Related]
8. KS900: A hypoxia-directed, reductively activated methylating antitumor prodrug that selectively ablates O(6)-alkylguanine-DNA alkyltransferase in neoplastic cells.
Baumann RP; Ishiguro K; Penketh PG; Shyam K; Zhu R; Sartorelli AC
Biochem Pharmacol; 2011 May; 81(10):1201-10. PubMed ID: 21396917
[TBL] [Abstract][Full Text] [Related]
9. Reductive activation of the prodrug 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]carbonyl]hydrazine (KS119) selectively occurs in oxygen-deficient cells and overcomes O(6)-alkylguanine-DNA alkyltransferase mediated KS119 tumor cell resistance.
Baumann RP; Penketh PG; Ishiguro K; Shyam K; Zhu YL; Sartorelli AC
Biochem Pharmacol; 2010 Jun; 79(11):1553-61. PubMed ID: 20005211
[TBL] [Abstract][Full Text] [Related]
10. 4-nitrobenzyloxycarbonyl derivatives of O(6)-benzylguanine as hypoxia-activated prodrug inhibitors of O(6)-alkylguanine-DNA alkyltransferase (AGT), which produces resistance to agents targeting the O-6 position of DNA guanine.
Zhu R; Liu MC; Luo MZ; Penketh PG; Baumann RP; Shyam K; Sartorelli AC
J Med Chem; 2011 Nov; 54(21):7720-8. PubMed ID: 21955333
[TBL] [Abstract][Full Text] [Related]
11. Lethality to leukemia cell lines of DNA interstrand cross-links generated by Cloretazine derived alkylating species.
Penketh PG; Baumann RP; Ishiguro K; Shyam K; Seow HA; Sartorelli AC
Leuk Res; 2008 Oct; 32(10):1546-53. PubMed ID: 18479747
[TBL] [Abstract][Full Text] [Related]
12. Chloroethylating and methylating dual function antineoplastic agents display superior cytotoxicity against repair proficient tumor cells.
Zhu R; Baumann RP; Patridge E; Penketh PG; Shyam K; Ishiguro K; Sartorelli AC
Bioorg Med Chem Lett; 2013 Mar; 23(6):1853-9. PubMed ID: 23395657
[TBL] [Abstract][Full Text] [Related]
13. Protection of CHO cells by mutant forms of O6-alkylguanine-DNA alkyltransferase from killing by 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) plus O6-benzylguanine or O6-benzyl-8-oxoguanine.
Loktionova NA; Xu-Welliver M; Crone TM; Kanugula S; Pegg AE
Biochem Pharmacol; 1999 Jul; 58(2):237-44. PubMed ID: 10423163
[TBL] [Abstract][Full Text] [Related]
14. Expression of mammalian O6-alkylguanine-DNA alkyltransferase in a cell line sensitive to alkylating agents.
Dolan ME; Norbeck L; Clyde C; Hora NK; Erickson LC; Pegg AE
Carcinogenesis; 1989 Sep; 10(9):1613-9. PubMed ID: 2766456
[TBL] [Abstract][Full Text] [Related]
15. Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity. In Chinese hamster ovary cells expressing wild-type and mutant O6-alkylguanine-DNA alkyltransferases.
Cai Y; Wu MH; Xu-Welliver M; Pegg AE; Ludeman SM; Dolan ME
Cancer Res; 2000 Oct; 60(19):5464-9. PubMed ID: 11034089
[TBL] [Abstract][Full Text] [Related]
16. Quantitative relationship between guanine O(6)-alkyl lesions produced by Onrigin™ and tumor resistance by O(6)-alkylguanine-DNA alkyltransferase.
Ishiguro K; Zhu YL; Shyam K; Penketh PG; Baumann RP; Sartorelli AC
Biochem Pharmacol; 2010 Nov; 80(9):1317-25. PubMed ID: 20654586
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia.
Giles F; Verstovsek S; Thomas D; Gerson S; Cortes J; Faderl S; Ferrajoli A; Ravandi F; Kornblau S; Garcia-Manero G; Jabbour E; O'Brien S; Karsten V; Cahill A; Yee K; Albitar M; Sznol M; Kantarjian H
Clin Cancer Res; 2005 Nov; 11(21):7817-24. PubMed ID: 16278404
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy-induced O(6)-benzylguanine-resistant alkyltransferase mutations in mismatch-deficient colon cancer.
Liu L; Schwartz S; Davis BM; Gerson SL
Cancer Res; 2002 Jun; 62(11):3070-6. PubMed ID: 12036916
[TBL] [Abstract][Full Text] [Related]
19. Carbamoylating activity associated with the activation of the antitumor agent laromustine inhibits angiogenesis by inducing ASK1-dependent endothelial cell death.
Ji W; Yang M; Praggastis A; Li Y; Zhou HJ; He Y; Ghazvinian R; Cincotta DJ; Rice KP; Min W
PLoS One; 2014; 9(7):e103224. PubMed ID: 25068797
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of human DNA polymerase beta activity by the anticancer prodrug Cloretazine.
Frederick AM; Davis ML; Rice KP
Biochem Biophys Res Commun; 2009 Jan; 378(3):419-23. PubMed ID: 19026985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
